Orano Med
- Company typePrivate
- Founded2009
- HeadquartersPlano, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Orano Med firmographics
Firmographics- Name
- Orano Med
- Legal name
- Orano Med
- Website
- https://oranomed.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Orano Med industry classification
Industry- Product category
- Targeted Alpha Therapy Radiopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)
Keywords
Where Orano Med is headquartered
LocationHeadquarters
- HQ city
- Plano
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
Orano Med business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales
Revenue model
- Licensing and Co-development Agreements: Orano Med generates revenue through licensing deals and co-development partnerships with pharmaceutical companies. Sanofi paid approximately €300 million for a minority stake and licensed AlphaMedix for global commercialization. The company co-develops programs with Roche and Molecular Partners under royalty arrangements.
- Lead-212 Isotope Supply: Orano Med supplies lead-212 isotopes and radiopharmaceutical manufacturing services to clinical trial partners. The company manufactures 212Pb-chelated products for its own trials and partner trials (Roche Phase 1, Molecular Partners trials) using its industrial platform in France and the United States.
- Future Product Revenue (Pre-commercial): Once AlphaMedix and other pipeline candidates receive regulatory approval, Orano Med will participate in commercial revenue through its partnership structure with Sanofi holding commercialization rights for AlphaMedix. Revenue will flow from radiopharmaceutical product sales to healthcare providers.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels9 records
Orano Med product offering
Product offeringCore offering
Orano Med develops and manufactures targeted alpha therapy (TAT) radiopharmaceuticals based on the lead-212 (212Pb) radioisotope for treating rare and difficult-to-treat cancers. The company controls the entire production chain — from extracting lead-212 chemically from thorium-232 raw material, through chelation with targeting molecules (peptides, antibodies, DARPins), to GMP manufacturing of finished drug product. Its lead asset AlphaMedix is licensed to Sanofi for global commercialization, and additional pipeline programs are co-developed with Roche and Molecular Partners.
Product overview
Orano Med is a clinical-stage biotechnology company developing a new generation of targeted cancer therapies using lead-212 (212Pb) alpha-emitting radioisotope, known as targeted alpha therapy (alphathérapie ciblée). The company operates as a subsidiary of French nuclear group Orano and maintains a diversified pipeline of 212Pb-based radiopharmaceuticals targeting various cancer types. The core product AlphaMedix (212Pb-DOTAMTATE) targets neuroendocrine tumors and is licensed to Sanofi. Additional pipeline programs include 212Pb-GRPR for solid tumors (Phase 1), 212Pb-CEA-PRIT for colorectal cancer (with Roche), 212Pb-DARPin-DLL3 (MP0712) for small cell lung cancer (with Molecular Partners), 212Pb-PSMA for prostate cancer (Pre-IND), and 212Pb-DARPin-MSLN for ovarian cancer (PoC). Orano Med controls the entire supply chain from thorium-232 to finished radiopharmaceutical, operating industrial facilities in France (Laboratoire Maurice Tubiana, ATEF, ATLab Valenciennes) and the US (DDPU Plano, ATLab Indianapolis).
Differentiator
Problem solved
Functional benefit
Brands
- AlphaMedix: Lead-212 based radioligand therapy for neuroendocrine tumors, the company's most advanced clinical candidate.
- Laboratoire Maurice Tubiana (LMT)
- Advanced Thorium Extraction Facility (ATEF)
- Drug Development & Preclinical Unit (DDPU)
- Alpha Therapy Laboratory (ATLab)
Products and services
- AlphaMedix (212Pb-DOTAMTATE) Targeted alpha therapy using lead-212 conjugated to a somatostatin receptor-binding peptide (DOTAMTATE) for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Achieved Phase 2 success with 60% ORR in RLT-naïve patients and 34.6% ORR in RLT-exposed patients. Received FDA Breakthrough Therapy Designation in February 2024. Licensed to Sanofi for global commercialization.
- 212Pb-GRPR Gastrin-releasing peptide receptor (GRPR)-targeting peptide labeled with lead-212 for treating multiple solid tumor types including metastatic castration-resistant prostate cancer, HR+/HER2- breast cancer, colorectal cancer, cervical cancer, cutaneous melanoma, and non-small cell lung cancer. Currently in Phase 1 clinical trials in the United States.
- 212Pb-CEA-PRIT Two-step pretargeted radioimmunotherapy using lead-212 to target carcinoembryonic antigen (CEA)-positive cancers including colorectal, pancreatic, gastric, and certain lung cancers. Developed in partnership with Roche using Roche's SPLIT antibody pretargeting technology. Advancing to Phase 1 clinical trial expected in H1 2026.
- 212Pb-DARPin-DLL3 (MP0712) DLL3-targeting Radio-DARPin therapeutic candidate co-developed with Molecular Partners using lead-212 targeted alpha therapy for small cell lung cancer and other neuroendocrine cancers expressing DLL3. Phase 1/2a trial ongoing with initial clinical data expected in 2026.
- 212Pb-PSMA Prostate-specific membrane antigen (PSMA)-targeting peptide labeled with lead-212 for prostate cancer treatment. Currently in Pre-IND stage of development.
- 212Pb-DARPin-MSLN (MP0726) Mesothelin-targeting Radio-DARPin candidate co-developed with Molecular Partners for ovarian cancer and other MSLN-expressing cancers. Preclinical data presented at SNMMI 2025 showed promising tumor accumulation and selective binding in vivo.
Quantifiable outcome
- Phase 2 AlphaMedix achieved 60% objective response rate (ORR) in RLT-naïve GEP-NET patients and 34.6% ORR in RLT-exposed patients, with primary endpoints met in both local and blinded independent central review.
- +3 more outcomes
Companies that use Orano Med
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Orano Med technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Orano Med partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- RochecoreLong-standing collaboration (since 2012) to develop two-step pretargeted radioimmunotherapy (PRIT) using lead-212 targeting carcinoembryonic antigen (CEA) in colorectal, pancreatic, gastric, and certain lung cancers. The partnership advanced from preclinical research to clinical development in Q3 2025. Roche sponsors the Phase 1 trial expected to start H1 2026. Orano Med manufactures and distributes chelated 212Pb from its French and US platforms. A shared R&D laboratory in Razès, France was built as part of the alliance.
- RadioMedixcoreThree-way collaboration with Orano Med and Sanofi for AlphaMedix (212Pb-DOTAMTATE). RadioMedix, a Houston-based clinical-stage radiopharmaceutical company, originally developed the AlphaMedix asset. The partnership combines RadioMedix's targeting molecule expertise, Orano Med's lead-212 production capabilities, and Sanofi's pharmaceutical commercialization power. AlphaMedix is in late-stage development for GEP-NETs.
- Molecular PartnerscoreStrategic collaboration to develop up to 10 targeted alpha radio-therapy programs using Molecular Partners' DARPin protein platform with Orano Med's lead-212. The most advanced candidate, MP0712 (DLL3-targeted Radio-DARPin for small cell lung cancer and neuroendocrine tumors), entered a Phase 1/2a trial in 2025. A second program targets mesothelin (MSLN). Molecular Partners leads development with royalty arrangements; Orano Med has option to co-develop two programs on a 50/50 basis with commercialization rights. Initial collaboration expanded by 6 new programs in 2025.
- MacrocyclicscoreSubsidiary acquired in 2011, based in Plano, Texas alongside the DDPU. Macrocyclics provides advanced chelating technology for nuclear medicine, producing the chelants used in Orano Med's lead-212 therapies. Its expertise in chelation chemistry is critical to stable binding of lead-212 to targeting molecules. The company has been providing chelating technology since 1995.
Scale indicators9 records
Recent moves7 records
Expansion highlights5 records
Orano Med competitors and assessment
Company assessmentBroad incumbents
- Curium: Curium is a global nuclear medicine player producing diagnostic and therapeutic radiopharmaceuticals at commercial scale. Comparable as a vertically integrated radiopharma manufacturer/distributor with overlapping manufacturing and isotope capabilities.
- Novartis: Novartis commercializes Pluvicto (177Lu-PSMA-617) and Lutathera (177Lu-DOTATATE), the leading radioligand therapies. Directly comparable as the dominant incumbent in targeted radiotherapy that Orano Med's lead-212 alpha therapies aim to disrupt or complement.
- Bayer: Bayer developed and commercialized Xofigo (radium-223 dichloride), the first alpha-emitting radiopharmaceutical for cancer. Highly comparable as the historical alpha-therapy benchmark, with Bayer's former radiopharmaceutical head (now Orano Med's CMO) directly connecting the two.
Direct peers
- Perspective Therapeutics: Perspective Therapeutics is developing lead-212-based radiopharmaceuticals targeting PSMA and other antigens. The most direct head-to-head competitor on the same isotope, indicating platform validation but also near-term competitive overlap.
- Fusion Pharmaceuticals (acquired by AstraZeneca): Fusion developed actinium-225-based targeted alpha therapies for cancer and was acquired by AstraZeneca. Highly comparable as a competing alpha-emitter radiopharma platform that exited via a major pharma acquisition, validating the M&A pathway for Orano Med.
- Lantheus Holdings: Lantheus is a commercial-stage radiopharmaceutical company with a portfolio spanning diagnostic and therapeutic agents (e.g., PNT2002/SOLAR-1 in PSMA). Comparable as a vertically integrated radiopharma player pursuing theranostic and targeted radioligand therapy.
- Telix Pharmaceuticals: Telix develops and commercializes radiopharmaceuticals including Illuccix (PSMA-PET imaging) and is advancing therapeutic programs. Comparable as a commercial-stage radiopharma competitor with overlapping theranostic ambitions and urological oncology focus.
- ITM Isotope Technologies Munich: ITM is a radiopharmaceutical company specializing in radionuclide supply (lutetium-177 and others) and targeted radiopharmaceutical development. Comparable as both a competing isotope supplier and a developer of targeted radioligand therapies.
- Point Biopharma (acquired by Eli Lilly): POINT Biopharma developed PSMA-targeted radioligand therapy (PNT2002) and actinium-225 alpha therapy programs before Eli Lilly's acquisition. Comparable as a clinically staged radioligand therapy competitor that validates pharma appetite for the category.
Others
- Molecular Partners: Molecular Partners is Orano Med's development partner on the Radio-DARPin platform (up to 10 programs including MP0712). Comparable as the targeting-molecule engine that powers a subset of Orano Med's pipeline, with reciprocal alignment on program economics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Orano Med social profiles
Digital presenceOrano Med financial estimates
Financial estimateRevenue estimate
Valuation estimate
Orano Med leadership team
Management profileNumber of profiles
Profiles21 records
Orano Med subsidiaries and ownership
Company hierarchySubsidiaries1 record
Orano Med funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Orano Med M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Orano Med
What does Orano Med do?
Orano Med develops and manufactures targeted alpha therapy (TAT) radiopharmaceuticals based on the lead-212 (212Pb) radioisotope for treating rare and difficult-to-treat cancers. The company controls the entire production chain — from extracting lead-212 chemically from thorium-232 raw material, through chelation with targeting molecules (peptides, antibodies, DARPins), to GMP manufacturing of finished drug product. Its lead asset AlphaMedix is licensed to Sanofi for global commercialization, and additional pipeline programs are co-developed with Roche and Molecular Partners.
Is Orano Med a public or private company?
Orano Med is a private company. It is classified as corporate owned and is currently operating.
When was Orano Med founded?
Orano Med was founded in 2009. It employs 101 to 250 people.
Where is Orano Med based?
Orano Med is headquartered in Plano, United States, in the North America region.
How does Orano Med make money?
Three revenue lines are on record. Licensing and Co-development Agreements are the primary driver. The others are lead-212 Isotope Supply and future Product Revenue (Pre-commercial).
Who are Orano Med's main competitors?
Broad incumbents on record are Curium, Novartis and Bayer. Direct peers are Perspective Therapeutics, Fusion Pharmaceuticals (acquired by AstraZeneca), Lantheus Holdings, Telix Pharmaceuticals, ITM Isotope Technologies Munich and Point Biopharma (acquired by Eli Lilly). Molecular Partners is listed as an others.
Does Orano Med have an API?
No public API is recorded for Orano Med.
What industry is Orano Med in?
Orano Med's product category is Targeted Alpha Therapy Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish). Its NAICS code is 325412 and its SIC code is 2834.